Psychedelic Medicine and Therapy: What Each Position Is Protecting

On June 4, 2024, the FDA's Psychopharmacologic Drugs Advisory Committee convened to consider whether to recommend approval of MDMA-assisted therapy for post-traumatic stress disorder. Veterans, first responders, and survivors of sexual assault testified about experiences they described as transformative — a single guided MDMA session had done what years of conventional therapy could not. The room carried the weight of that testimony.

The committee voted 9-2 against recommending approval.

The concerns were methodological: blinding was impossible (everyone who took MDMA knew it), therapist misconduct had been documented in the clinical trials, the mechanisms of action were poorly understood, and long-term safety data were thin. The FDA followed two months later with a Complete Response Letter — a formal rejection — asking for additional Phase 3 trials. For a movement that had spent a decade believing it was on the verge of a therapeutic revolution, this was a significant reckoning.

The setback did not end the debate. It clarified its shape. The psychedelic medicine conversation had always contained multiple disputes that the optimism of the research renaissance had temporarily papered over: disputes about the standard of evidence, about who would be able to afford access, about whether the FDA approval model was even the right framework, and about what the entire enterprise means for Indigenous communities whose ceremonial use of these substances predates the clinical trials by centuries. These disputes did not begin with the FDA rejection. They had been waiting for a reversal to make them visible.

What the psychedelic medicine advocates are protecting

The case for psychedelic-assisted therapy begins with a treatment gap that is not rhetorical. Post-traumatic stress disorder affects roughly 13 million Americans in any given year, according to the National Center for PTSD. Conventional pharmacotherapy — primarily SSRIs — achieves full remission in a minority of patients, and response rates in treatment-resistant PTSD are lower still. The veterans' suicide crisis, which claimed more lives between 2005 and 2017 than combat in Iraq and Afghanistan combined, has proven largely resistant to existing interventions. The same is true for treatment- resistant depression, where ketamine infusions have already received FDA approval for esketamine (Spravato) and opened the regulatory door that MDMA and psilocybin researchers are trying to walk through.

The research renaissance began in earnest in the 2010s, after decades in which the Controlled Substances Act's Schedule I classification for psilocybin, MDMA, and LSD effectively halted human research. The Johns Hopkins Center for Psychedelic and Consciousness Research, founded in 2019 with $17 million in private funding, and Rick Doblin's Multidisciplinary Association for Psychedelic Studies (MAPS), which ran the MDMA trials, produced results that were striking by the standards of psychiatric pharmacology: a 2021 Phase 3 trial of MDMA-assisted therapy found that 67 percent of participants no longer met diagnostic criteria for PTSD at the two-month follow-up, compared to 32 percent in the placebo arm. Johns Hopkins psilocybin studies for treatment-resistant depression produced similarly dramatic results.

What this position is protecting is the claim that the drug scheduling system has for fifty years blocked access to treatments that patients with treatment-resistant conditions desperately need — and that the evidence base, while imperfect, is sufficiently strong to justify a supervised clinical pathway. The FDA's 2017 Breakthrough Therapy Designation for MDMA-assisted PTSD therapy and its 2018 and 2019 Breakthrough designations for psilocybin in major depressive disorder represented the agency's own acknowledgment that preliminary evidence was compelling enough to warrant expedited review. The advocates are protecting that designation against what they characterize as institutional inertia and methodological standards that were built for compounds very different from psychedelics — drugs that are taken daily, not in one or two supervised sessions.

What this position costs: MAPS's Lykos Therapeutics, the for-profit spinoff created to commercialize MDMA therapy, faced credible accusations of therapist misconduct during trials — at minimum two therapists had inappropriate contact with patients — and questions about whether adverse events were fully reported. The FDA rejection cited these concerns explicitly. The movement's case depends on the integrity of the clinical evidence, and where the evidence was generated under conditions that compromised that integrity, the case is weakened in ways that cannot be addressed simply by arguing that the therapy works.

What the clinical rigor advocates are protecting

A second camp takes no position on whether psychedelics can be useful medicines. Their concern is with the epistemic standards being used to evaluate them. The FDA rejection articulated this concern precisely, and it was echoed by biostatisticians, clinical trial methodologists, and some psychiatrists who had been watching the research closely.

The methodological problems are real and structural. The gold standard of clinical trials — the double-blind randomized controlled trial — depends on neither patients nor researchers knowing who received the active compound. With MDMA, this is impossible: the psychoactive effects are unmistakable, and active placebos (low doses of MDMA, niacin, or other compounds used in various trials) do not produce convincing blinding. In a 2021 paper in The Lancet Psychiatry, researchers found that functional unblinding was near-total in MDMA trials — the vast majority of participants correctly identified whether they had received MDMA. This does not mean the therapeutic effects are placebo; it means that the standard tool for isolating drug effects from expectation effects is unavailable.

The concern is not merely academic. Set and setting — the widely-used framework that attributes psychedelic effects partly to psychological preparation and therapeutic context — may mean that much of what drives outcomes is the intensive, supportive therapeutic relationship that accompanies the drug session, rather than the pharmacology itself. If so, the drug component is a catalyst for something that other intensive therapies might also produce, and the question becomes whether the chemical is necessary or whether the therapeutic architecture deserves more attention than the compound.

What this position is protecting is the FDA approval process as a genuine patient protection mechanism — not regulatory capture or institutional inertia, but the hard-won principle that the bar for approval should be high enough that what gets approved actually works the way the approval claims. The history of psychiatry includes multiple examples of treatments that appeared transformative in early trials and proved far more complicated in practice: lobotomy, insulin coma therapy, SSRIs in adolescents. The clinical rigor advocates are protecting the integrity of a system that exists precisely because medicine's track record with early enthusiasm is not reassuring.

What this position costs: it can be wielded against any novel treatment as a reason for delay that also benefits entrenched pharmaceutical interests. The argument that we need more trials can function as indefinite deferral of a therapy that the existing evidence suggests is helping patients who have no other good options. The FDA's own Breakthrough designation acknowledged this — it was designed for exactly this situation. The methodological critique is valid, but the question of how high the bar should be for a population with no effective alternatives is not resolved by pointing at the methodological problems.

What the drug war critics are protecting

A third camp approaches psychedelic medicine with a different set of concerns — not about whether MDMA or psilocybin are therapeutically useful, but about what it means that access to these substances is being routed through an FDA-approved clinical pathway rather than through decriminalization or broader legal reform.

The economics are stark. Ketamine infusion therapy, which is legally available but rarely covered by insurance, typically costs $400–800 per session and requires multiple sessions. MAPS estimated that an FDA-approved MDMA therapy course — two to three supervised sessions with preparatory and integration therapy — would cost between $10,000 and $15,000 out of pocket. Psilocybin therapy under Oregon's Measure 109 framework, which created licensed service centers for supervised psilocybin experiences (not a medical model, but not full decriminalization either), is priced similarly. The populations most likely to benefit — veterans with chronic PTSD, people with substance use disorders, low-income patients who have cycled through inadequate mental health treatment — are the populations least likely to be able to afford this therapy at those prices.

The racial dimension compounds this. Black and Latino Americans have been prosecuted under drug laws at dramatically higher rates than white Americans for possession of the same substances. The psychedelic therapy movement has been overwhelmingly white in its researchers, practitioners, and early patient populations. The trajectory from criminalization to expensive medical treatment manages to keep the benefits on one side of the racial wealth gap and the costs on the other — criminalization disproportionately affecting communities of color, therapeutic access disproportionately available to the affluent. This critique does not require anyone in the movement to be consciously racist; it is structural.

What this position is protecting is a vision of access equity — the idea that a substance can be either available to everyone or available to no one, and that routing availability through a costly medical licensing system is a choice that distributes benefits upward. The decriminalization campaigns in Denver (psilocybin, 2019), Oregon (Measure 110, 2020), and Colorado (Proposition 122, 2022) represent a parallel track to the FDA pathway — one that prioritizes access over the medicalized governance model.

What this position costs: decriminalization without support structures produces its own equity problems. People with strong social networks, financial resources, and access to knowledgeable guides will navigate unregulated access far better than people without those supports. A difficult psychedelic experience without a trained guide or safe setting is genuinely dangerous for some populations. The clinical model, whatever its access problems, provides something that decriminalization does not: structured support for the people who need it most. The drug war critique identifies a real failure of the medicalized pathway but has not produced a fully satisfying alternative framework.

What the Indigenous sovereignty advocates are protecting

The psychedelic renaissance has proceeded largely as if the substances at its center had no history before Western pharmaceutical chemistry took an interest in them. They do.

Peyote — the cactus containing mescaline — has been used in ceremonial contexts by Indigenous peoples of North America for at least five thousand years. The Native American Church, which counts an estimated 250,000 to 400,000 members, has conducted peyote ceremonies continuously throughout a century of legal harassment and prohibition, securing explicit legal protection in the American Indian Religious Freedom Act Amendments of 1994. Psilocybin mushrooms have documented ceremonial use among the Mazatec people of Oaxaca stretching back centuries, brought to broader Western attention in part by R. Gordon Wasson's 1957 Life magazine article about a ceremony conducted by María Sabina — a disclosure made without her understanding of its consequences and which Sabina later described as a desecration of her practice.

Ayahuasca, the DMT-containing brew from Amazonian traditions, occupies a legal gray zone in the United States while being the subject of a multi-billion-dollar spiritual tourism industry that has drawn hundreds of thousands of Western seekers to Peru, Brazil, and Colombia in the past two decades — often with inadequate understanding of the ceremonial contexts, with predatory practitioners exploiting that gap, and with economic flows that benefit retreat centers and tour operators while returning little to the communities that developed and maintain the tradition.

What this position is protecting is several distinct things that are often conflated. First, the concrete and material: peyote cactus is critically overharvested, takes ten to fifteen years to reach harvestable size, and faces pressure both from the "wellness tourism" demand for mescaline experiences and from the decline of the native Texas habitat where it grows. The Native American Church has been explicit that non-Indigenous decriminalization of peyote — which would open broader access — threatens the sacrament's availability for the communities for whom it has ceremonial significance. Second, the intellectual and spiritual: the frameworks through which Indigenous communities understand these practices — relational rather than individual, embedded in cosmological systems rather than psychiatric categories — are erased when the substances are extracted from their contexts and administered in clinical trials designed to produce FDA-approvable data.

What this position costs: it can function as a veto on research and access for people who have no connection to Indigenous traditions. A veteran with treatment-resistant PTSD did not participate in the desecration of Mazatec ceremony. The Indigenous sovereignty critique raises legitimate questions about attribution, access, and intellectual property, but the claim that Western clinical use of psilocybin constitutes harm to Indigenous communities is more complicated than either the advocates or critics of psychedelic medicine typically acknowledge.

What the psychiatric conservatives are protecting

A fifth position comes from within mainstream psychiatry — not from opponents of drug policy reform or from cultural critics, but from clinicians who take the treatment gap seriously and remain skeptical of the psychedelic medicine movement's claims.

The concern begins with patient safety. Psychedelics are genuinely contraindicated for a subset of patients: individuals with personal or family history of schizophrenia, bipolar disorder with psychotic features, or certain other conditions are at elevated risk for adverse reactions, including acute psychosis and prolonged psychotic episodes. The clinical trials conducted to date were highly selective — they excluded patients with these risk factors — which means the populations who are most vulnerable to harm are the least represented in the evidence base being used to advocate for broader access. What happens when psychedelic therapy moves from highly controlled research environments to real-world clinical practice, with the populations who weren't in the trials and the practitioners who weren't trained at Johns Hopkins, is not answered by the trial data.

There is also a concern about the mechanism claims. Much of the advocacy for psychedelic medicine draws on concepts — "ego dissolution," "mystical experience," "neuroplasticity windows," "default mode network disruption" — that range from mechanistically underspecified to philosophically contested. The mystical experience questionnaire, used in Johns Hopkins studies to assess whether a therapeutic session was "complete," treats the phenomenology of the experience as therapeutically central. Some psychiatrists find this framework scientifically incoherent: it conflates a philosophical or spiritual category (mystical experience) with a treatment mechanism in ways that are not falsifiable and that make it difficult to optimize the therapeutic protocol.

What this position is protecting is the biomedical coherence of psychiatry at a moment when its evidence base is genuinely shaky. Psychiatric medications have underperformed their early promise across multiple drug classes — the SSRI story is one of modest average effects with high individual variation and widespread inappropriate use. The movement toward psychedelics carries the same risk of premature enthusiasm that has characterized psychiatry's repeated hype cycles. The conservative position is protecting the institutional reputation of a field that has learned from those cycles to be skeptical of transformative claims.

What this position costs: it can function as status quo defense in a situation where the status quo — inadequate treatment for treatment-resistant conditions — is actively harmful. The argument that more data are needed before proceeding is reasonable in the abstract; it is harder to defend when the alternative is continued suffering for a population for whom the existing pharmacopeia has failed. Psychiatric conservatism is also not neutral with respect to pharmaceutical industry interests, which benefit from the continued dominance of patent-protected medications over substances that, in their natural forms, cannot be patented.

Where the tensions actually live

Several structural features of this debate make it resistant to the resolution that advocates on all sides tend to assume is just around the corner.

The first is the blinding problem, which is not merely methodological. It exposes something real about what psychedelic therapy is. If the treatment effects depend on the experience of taking a powerful psychoactive compound in a supportive therapeutic context, then the "drug" component and the "therapy" component are not separable in the way the clinical trial architecture assumes. This is not a failure of trial design; it is a feature of the treatment. It means that the FDA approval pathway — which was built to evaluate chemicals with isolable pharmacological mechanisms — may be the wrong tool for evaluating an intervention that is partly pharmacological and partly experiential. Oregon's Measure 109, which created "psilocybin service centers" rather than a medical prescription pathway, is an implicit recognition of this problem. It is neither fully medical nor fully decriminalized — it is a governance innovation for a situation the existing regulatory categories do not fit well.

The second is the access and equity problem, which intersects with the clinical model in a way that the research community has been slow to address. The populations most likely to benefit from psychedelic therapy — veterans, people with histories of trauma, people with substance use disorders — are not the populations who will be able to afford $10,000-$15,000 therapy courses. This is a predictable consequence of the for-profit development pathway: Lykos Therapeutics licensed MAPS's research and intended to capture a commercial return on it, which requires pricing the therapy at a level that commercial return requires. The structural tension between the altruistic framing of the research enterprise and the commercial logic of the development pathway was not adequately addressed before the FDA rejection made it salient.

The third is the indigeneity and attribution question, which does not have a clean resolution. The intellectual and spiritual heritage of psychedelic plant medicines belongs, in some morally significant sense, to the communities that developed them. How that belonging translates into legal rights, royalties, access protections, or constraints on clinical research is not obvious. The Nagoya Protocol on access and benefit sharing, developed under the Convention on Biological Diversity, provides a framework for genetic resources that has been partially extended to traditional knowledge, but its application to ceremonial practices mediated by specific plants is contested and largely unenforced. The psychedelic medicine movement has not resolved this question; it has mostly deferred it.